Altered glucose metabolism in cancer cells is termed the Warburg effect, which describes the propensity of most cancer cells to take up glucose avidly and convert it primarily to lactate, despite available oxygen 1, 2 . Notwithstanding the renewed interest in the Warburg effect, cancer cells also depend on continued mitochondrial function for metabolism, specifically glutaminolysis that catabolizes glutamine to generate ATP and lactate 3 . Glutamine, which is highly transported into proliferating cells 4, 5 , is a major source of energy and nitrogen for biosynthesis, and a carbon substrate for anabolic processes in cancer cells, but the regulation of glutamine metabolism is not well understood 1, 6 . Here we report that the c-Myc (hereafter referred to as Myc) oncogenic transcription factor, which is known to regulate microRNAs 7, 8 and stimulate cell proliferation 9 , transcriptionally represses miR-23a and miR-23b, resulting in greater expression of their target protein, mitochondrial glutaminase, in human P-493 B lymphoma cells and PC3 prostate cancer cells. This leads to upregulation of glutamine catabolism 10 . Glutaminase converts glutamine to glutamate, which is further catabolized through the tricarboxylic acid cycle for the production of ATP or serves as substrate for glutathione synthesis 11 . The unique means by which Myc regulates glutaminase uncovers a previously unsuspected link between Myc regulation of miRNAs, glutamine metabolism, and energy and reactive oxygen species homeostasis.
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Oncogenes and tumour suppressors have been linked to the regulation of glucose metabolism, thereby connecting genetic alterations in cancers to their glucose metabolic phenotype 1, 2 . In particular, the MYC oncogene produces Myc protein that directly regulates glucose metabolic enzymes as well as genes involved in mitochondrial biogenesis 9, 12 . In this regard, we sought to determine the role of MYC in altering the mitochondrial proteome in order to understand further the regulation of tumour metabolism. We studied human P-493 B cells that bear a tetracycline-repressible MYC construct, such that tetracycline withdrawal results in rapid induction of Myc and mitochondrial biogenesis, followed by cell proliferation 12, 13 . By comparing the mitochondrial proteomes of tetracycline-treated and untreated cells with high Myc expression, we found eight mitochondrial proteins that are distinctly differentially expressed in response to Myc (Fig. 1a, b and Supplementary Table 1) . Mitochondrial glutaminase expression (GLS, molecular mass of ,58 kDa) was increased ,10-fold in response to Myc. As such, we determined the response of glutaminase to Myc induction in a time-course study using anti-GLS antibody 10 ( Fig. 1c) and found that GLS levels diminish with decreased Myc expression and recover on Myc re-induction.
However, the level of the mitochondrial protein TFAM remained virtually unaltered. GLS levels also correlate with Myc levels in another human B cell line (CB33) and one (CB33-Myc) with constitutive Myc expression 14 . Because human prostate cancer is linked to Myc expression 15 , we sought to determine whether reduction of Myc expression by short interfering RNA (siRNA) in the human PC3 prostate cancer cell line is also associated with reduction of GLS expression (Fig. 1d) . Similar to the human lymphoid cells, the PC3 cells also displayed a correlation between Myc and GLS levels.
We then sought to determine whether the marked alteration of GLS levels in response to Myc is functionally linked to Myc-induced cell proliferation. Although there are two major known tissue-specific GLS isoforms, GLS1 and GLS2 (refs 16, 17) , our data show that only GLS1 is predominantly expressed in P493-6 or PC3 cells ( Supplementary Fig. 1 ). We first determined whether gain of GLS1 function through overexpression in PC3 cells would rescue the diminished growth rate associated with siRNA-mediated reduction of Myc ( Supplementary Fig. 2 ) and found that ectopic GLS1 expression alone is insufficient to stimulate growth. In light of the observation that no single gene could substitute for Myc 18, 19 and that Myc is a pleiotropic transcription factor 9 , this outcome was not particularly surprising. As such, we reduced the expression of GLS1 (hereafter referred to as GLS) by RNA interference (GLS siRNA) and found that P-493-6 cell proliferation is markedly attenuated by GLS siRNA but not by control siRNA (Fig. 2a) . Likewise, proliferation of the human PC3 prostate cancer cell line was diminished by GLS siRNA (Fig. 2a) , indicating that GLS is necessary for cell proliferation.
Because glutamine is converted by GLS to glutamate for further catabolism by the tricarboxylic acid (TCA) cycle, and previous studies indicate that overexpression of Myc sensitizes human cells to glutamine-withdrawal-induced apoptosis 11 , we determined the metabolic responses of P493-6 or PC3 cells to glutamine deprivation (Fig. 2b) . The growth of both cell lines was diminished significantly by glutamine withdrawal and moderately with glucose withdrawal. Glutamine withdrawal also resulted in a decrease in ATP levels ( Fig. 2c ) associated with a diminished cellular oxygen consumption rate ( Supplementary Fig. 3a, b) . Reduction of GLS by RNA interference (RNAi) also reduced ATP levels (Fig. 2d) . Because glutamine is a precursor for glutathione 20 , glutathione levels were measured by flow cytometry and were found to be diminished with glutamine withdrawal or RNAi-mediated reduction of GLS ( Supplementary Fig. 4 and Supplementary Table 2 ) that is also associated with an increase in reactive oxygen species (ROS) levels ( Supplementary Fig. 3c ) and cell death in the P493-6 cells ( shortly after the MYC proto-oncogene was discovered, the MC29 retrovirus which bears the v-myc oncogene was found to enhance glutamine catabolism and mitochondrial respiration in transplantable avian liver tumour cells 21 . Thus, our findings functionally link historical observations with Myc, glutaminase and glutamine metabolism.
Because GLS catabolizes glutamine for ATP and glutathione synthesis, its reduction affects proliferation and cell death presumably through depletion of ATP and augmentation of ROS, respectively. Hence, we sought to rescue the P493-6 cells with the TCA cycle metabolite oxaloacetate (OAA) and the oxygen radical scavenger N-acetylcysteine (NAC) 11 . Both OAA and NAC partially rescued the decreased proliferation and death of P493-6 cells deprived of GLS (Fig. 2e and Supplementary Fig. 6 ). Similarly, OAA and NAC both partially rescued glutamine-deprived P493-6 cells ( Supplementary Figs 5 and 6 ). These findings support the notion that glutamine catabolism through GLS is critical for cell proliferation induced by Myc and protection against ROS generated by enhanced mitochondrial function in response to Myc 11, 20 . Given that GLS is critical for cell proliferation and is induced by Myc, we determined the mechanism by which Myc regulates GLS. Because Myc is a transcription factor 9 , we hypothesized that Myc transactivates GLS directly as a target gene. Despite the presence of a canonical Myc binding site (59-CACGTG-39) in the GLS gene intron 1, GLS messenger RNA levels do not respond to alterations in Myc levels in the P493-6 cells, suggesting that GLS is regulated at the post-transcriptional level (Fig. 3a) . As such, we hypothesized that GLS could be regulated by miRNAs that are in turn directly regulated by Myc. The TargetScan algorithm predicts that miR-23a and miR23b could target the GLS 39 untranslated region (UTR) seed sequence. Notably, our earlier studies uncovered that both miR23a and miR-23b are suppressed by Myc in P493-6 cells 7 , and both miR-23a and miR-23b are decreased in human prostate cancers 22 , which are associated with elevated Myc expression 15 . To verify that miR-23a and miR-23b (hereafter referred to as miR23a/b) are suppressed by Myc and can be diminished by antisense miR-23a/b locked nucleic acid (LNA) oligomers, a northern blot analysis was performed; the results show that miR-23a/b are indeed suppressed by Myc and profoundly diminished by antisense miR-23a/b LNAs (Fig. 3b) . Quantitative real-time polymerase chain reaction (PCR) assays show ( Supplementary Fig. 7 ) that miR-23a/b levels increase with diminished Myc expression and then decrease on Myc re-induction in a manner that is compatible with the GLS protein levels seen in Fig. 1c . We also found an inverse relationship between Myc and the levels of miR-23a/b in the CB33 human lymphoid cells and PC3 prostate cancer cell line ( Supplementary  Fig. 8 ). Furthermore, a chromatin immunoprecipitation assay (Fig. 3c) shows that Myc directly binds the transcriptional unit, C9orf3, encompassing miR-23b, as demonstrated for other Myc miRNA targets 7 . Because the transcriptional unit involving miR-23a has not been mapped, we did not study miR-23a in this context. These observations indicate that Myc represses miR-23a and miR-23b, which seem to be directly regulated by Myc.
We next determined whether miR-23a/b target and inhibit the expression of GLS through the 39 UTR. In this regard, we cloned the 39 UTR sequence of GLS including the predicted binding site for miR-23a/b to the pGL3 luciferase reporter vector and transfected MCF-7 cells, which are known to express miR-23a/b (ref. 23 ). The GLS 39 UTR inhibited luciferase activity in a fashion that was blocked by co-transfection with the antisense miR-23a/b LNAs, but not with control LNAs (Fig. 3d) . We next mutated the predicted binding site by a site-directed mutagenesis strategy 8 and observed that mutant 39 UTR does not inhibit luciferase activity as the wild-type sequence does. Using these reporters in PC3 cells, we observed that diminished expression of Myc via siRNA results in decreased luciferase activity with wild type but not with the mutant 39 UTR reporter ( Supplementary Fig. 9 ). Notably, reduced GLS protein level, a result of decreased Myc expression (Fig. 1c) , was rescued by antisense miR-23a/b LNAs (Fig. 3e) . The antisense miR-23a/b LNAs also partially rescued the diminished GLS level associated with RNAi-mediated reduction of Myc expression in PC3 cells (Fig. 3e) .
We also examined events upstream and downstream of GLS 24 and found that the glutamine transporter SLC7A5 is induced by Myc in P493-6 cells at the transcriptional level (fivefold by nuclear run-on, with a .7-fold induction of its mRNA level (K.I.Z. and C.V.D, unpublished data). The glutamine transporter ASCT2 (also called SLC1A5) shows a twofold induction by Myc at the mRNA level, whereas glutamate dehydrogenase mRNA levels appear unaltered (K.I.Z. and C.V.D., unpublished data). Furthermore, we found that elevated levels of Myc protein in human prostate cancer correspond to levels of GLS, which are not increased in the accompanying normal tissue from the same patients ( Supplementary Fig. 10 ). Intriguingly, miR-23a and miR-23b are significantly decreased in human prostate cancer as compared with normal prostate tissue 22 . It is notable that loss of GLS function by antisense suppression significantly inhibits the tumorigenesis of Ehrlich ascites tumour cells in vivo 25 . Our findings uncover a pathway by which Myc suppression of miR-23a/b, which target GLS, enhances glutamine catabolism through increased mitochondrial glutaminase expression. Taken together, these observations provide a regulatory mechanism involving Myc and miRNAs for elevated expression of glutaminase and glutamine metabolism in human cancers.
METHODS SUMMARY
Human cell lines were cultured under standard conditions. Isolation of mitochondria, enrichment for mitochondrial proteins, and proteomic analysis were performed as described [26] [27] [28] [29] . RNA interference experiments and luciferase reporter analysis of miRNA activity were as reported 8, 30 . Flow cytometric analyses of reactive oxygen species, cell death and glutathione level were performed as described 11, 30 . Human samples were acquired with the approval of the Johns Hopkins University School of Medicine Institutional Review Board.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
